Table 1:
Summary of Key HERV Investigations in Surgical Disease by Disease Type
| Disease | Review Number | Year | First Author | N | Tissues examined | Role for HERV | Application |
|---|---|---|---|---|---|---|---|
| Breast cancer | [38] | 2015 | Zhou | 21 | Tumor tissue | Yes | Immunologic therapy |
| Breast cancer | [39] | 2012 | Wang-Johanning | 223 | Tumor tissue | Yes | Immunologic target |
| Breast cancer | [44] | 2014 | Wang-Johanning | 155 | Tumor tissue, serum | N/A | Screening Biomarker |
| Melanoma | [53] | 2008 | Hahn | 312 | Serum | N/A | Biomarker |
| Melanoma | [56] | 2015 | Krishnamurthy | 359 | Tumor Tissue | N/A | Immunologic Target |
| Colorectal cancer | [63] | 2015 | Perot | 139 | Tumor tissue | Yes | Biomarker |
| Pancreatic cancer | [66] | 2017 | Li | 30 | Tumor tissue and Serum | Yes | Immunologic Target |
| Hepatocellular Carcinoma | [68] | 2016 | Ma | 84 | Tumor tissue | No | Biomarker for disease progression |
| Renal cell carcinoma | [82] | 2011 | Cherkasova | 67 | Tumor tissue | Yes | Immunologic Target |
| Prostate cancer | [91] | 2013 | Reis | 370 | Serum, tissue | Yes | Biomarker |
| Pulmonary Arterial Hypertension | [107] | 2017 | Saito | 18 | Disease tissue | Yes | Therapeutic target |
| Burns | [109] | 2014 | Lee | 11 | Serum | Yes | Biomarker |